Evidence map›Paper›PMID 37170483›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2023

Outcomes of the Indonesian Chronic Disease Management Program (PROLANIS) in Patients with Hypertension During the COVID-19 Pandemic in Rural Areas: A Preliminary Evaluation Study.

Sovia Salamah, Asiyah Nida Khafiyya, Ristra Ramadhani, Mega Rizkya Arfiana, Ibrahim Syamsuri, Novia Nurul Faizah, David Nugraha, Bustanul Arifin, Firas Farisi Alkaff

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Sovia SalamahDepartment of Public Health and Preventive Medicine, Faculty of Medicine Universitas Airlangga, Surabaya, East Java, Indonesia.ORCID 0000-0002-4815-8929
Asiyah Nida KhafiyyaUniversity of Chicago Center for Global Health, Chicago, IL, USA.
Ristra RamadhaniDepartment of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia.ORCID 0000-0002-7182-6227
Mega Rizkya ArfianaFaculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
Ibrahim SyamsuriDepartment of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia.ORCID 0000-0003-0095-240X
Novia Nurul FaizahFaculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.
David NugrahaFaculty of Medicine, Universitas Airlangga, Surabaya, East Java, Indonesia.ORCID 0000-0001-9194-2738
Bustanul ArifinFaculty of Pharmacy, Universitas Hasanuddin, Makassar, South Sulawesi, Indonesia.ORCID 0000-0002-2303-310X
Firas Farisi AlkaffDivision of Nephrology, Department of Internal Medicine, University Medical Center Groningen, Groningen, Netherlands.ORCID 0000-0002-5628-1345
Airlangga University · IDUniversity Medical Center Groningen · NLUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The Indonesian Chronic Disease Management Program (PROLANIS) is a government program that aims to improve the health outcomes of patients with chronic diseases, including hypertension. This preliminary study aimed to evaluate the impacts of the coronavirus disease 2019 (COVID-19) pandemic on the health outcomes of hypertension patients in rural areas who were enrolled in PROLANIS. MATERIAL AND METHODS This study used data from 4 PROLANIS groups in East Java province. The data were collected from participants' 6-month evaluations at 3 time points: before the COVID-19 pandemic in December 2019 (T0), during the COVID-19 pandemic in June 2020 (T1), and in December 2020 (T2). Evaluated parameters were body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low-density lipid (LDL), high-density lipid (HDL), triglyceride (TG), and estimated glomerular filtration rate (eGFR). RESULTS There were 91 patients included in the analyses. Compared to T0, BMI, blood pressure, eGFR, and TC had significantly deteriorated at T1, but LDL, HDL, and TG showed no marked changes. At T2, BMI, DBP, and TC were similar to T0. On the other hand, SBP and eGFR did not improve, while HDL significantly deteriorated. Stratified based on age, worsening of DBP, TC, and LDL at T1 and eGFR at T1 and T2 was only observed in those aged 60 years and older. CONCLUSIONS This preliminary study showed that the health outcomes of hypertension patients in rural areas who were enrolled in PROLANIS were negatively impacted during the COVID-19 pandemic, with the elderly being the most affected.

Indexed as

COVID-19HypertensionAgedBlood PressureCholesterol, HDLDisease ManagementHumansIndonesiaMiddle AgedPandemicsTriglyceridesCholesterol, HDLTriglycerides

Identifiers

PMID37170483
PMCPMC10187070
OpenAlexW4366991228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.